Filtered By:
Source: CNS Drugs
Drug: Donepezil

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1 results found since Jan 2013.

Pharmacotherapy for Vascular Cognitive Impairment
AbstractVascular cognitive impairment (VCI) is the second most common type of dementia after Alzheimer ’s disease (AD). Stroke and cardiovascular risk factors have been linked to both AD and VCI and potentially can affect cognitive function in mid and later life. Various pharmacological agents, including donepezil, galantamine, and memantine, approved for the treatment of AD have shown modest cogni tive benefits in patients with vascular dementia (VaD). However, their functional and global benefits have been inconsistent. Donepezil has shown some cognitive benefit in patients with VaD only, and galantamine has shown some...
Source: CNS Drugs - August 7, 2017 Category: Neurology Source Type: research